1. Home
  2. FGI vs BCDA Comparison

FGI vs BCDA Comparison

Compare FGI & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

N/A

Current Price

$5.51

Market Cap

14.0M

Sector

Industrials

ML Signal

N/A

BCDA

BioCardia Inc.

N/A

Current Price

$1.30

Market Cap

14.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FGI
BCDA
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.0M
14.5M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
FGI
BCDA
Price
$5.51
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
65.8K
67.3K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$135,654,095.00
N/A
Revenue This Year
$3.80
N/A
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.66
N/A
52 Week Low
$2.28
$1.00
52 Week High
$12.62
$3.20

Technical Indicators

Market Signals
Indicator
FGI
BCDA
Relative Strength Index (RSI) 45.22 42.35
Support Level $5.20 $1.26
Resistance Level $9.00 $1.50
Average True Range (ATR) 1.37 0.09
MACD -0.21 -0.01
Stochastic Oscillator 7.25 25.00

Price Performance

Historical Comparison
FGI
BCDA

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: